Advaxis Inc., a Princeton biotech specializing in drugs treating cancer and infectious diseases, announced today it has appointed Gregory T. Mayes to the new position of executive vice president and chief operating officer. Mayes joins Advaxis following the recent closing of a financing totaling $26.5 million and an uplisting to the NASDAQ Capital Market.
According to the announcement, Mayes has 15 years of experience as a biopharmaceutical executive with a background in the life sciences field. Mayes will report directly to Daniel J. O'Connor, the chief executive officer Advaxis appointed in August, and will be responsible for leading the company's business operations, including business development and licensing, legal affairs, commercial planning, information technology, and human resources. The company closed a public offering last week.